Patents by Inventor Jeremy Bastid

Jeremy Bastid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20210261686
    Abstract: The present invention relates to a CD39 antagonist for use for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell.
    Type: Application
    Filed: December 28, 2020
    Publication date: August 26, 2021
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
  • Antagonists of IL-17 isoforms and their uses
    Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES
    Publication number: 20180066051
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 8, 2018
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Antagonists of IL-17 isoforms and their uses
    Patent number: 9834601
    Abstract: The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: December 5, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • IL-17 ANTAGONIST ANTIBODIES
    Publication number: 20170233468
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 17, 2017
    Inventors: GILLES ALBERICI, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • IL-17 antagonist antibodies
    Patent number: 9676847
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 13, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES
    Publication number: 20150104456
    Abstract: The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Application
    Filed: June 11, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean- Francois Eliaou
  • IL-17 ANTAGONIST ANTIBODIES
    Publication number: 20150104457
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: June 25, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20130273062
    Abstract: Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 17, 2013
    Applicant: OREGA BIOTECH
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid